Interestingly, PRMT5 inhibition induced DNA replication stress in pancreatic cancer, and coadministration of PRMT5 inhibitor with CDC7 inhibitor XL413 exhibited promising therapy value. The gene discussed is CDC7; the disease is familial pancreatic carcinoma.